The most effective of these, termed HMIP-2 (HBS1L-MYB intergenic polymorphism, block 2) has been shown to influence disease severity in patients with SCD [11] and β thalassemia [8,12]. This evidence concerns the gene MYB and Schnyder corneal dystrophy.